Recent blog posts
Vascular dementia Indication Strategy Report 2026: TREM2, Trials and Deals
Latest Hotspot
8 min read
Vascular dementia Indication Strategy Report 2026: TREM2, Trials and Deals
21 July 2026
Vascular dementia indication strategy report covering epidemiology, TREM2 biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Lewy body dementia Indication Strategy Report 2026: α-synuclein, Trials and Deals
Latest Hotspot
8 min read
Lewy body dementia Indication Strategy Report 2026: α-synuclein, Trials and Deals
21 July 2026
Lewy body dementia indication strategy report covering epidemiology, α-synuclein biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Renal anemia Indication Strategy Report 2026: HIF-2α, Trials and Deals
Latest Hotspot
8 min read
Renal anemia Indication Strategy Report 2026: HIF-2α, Trials and Deals
21 July 2026
Renal anemia indication strategy report covering epidemiology, HIF-2α biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Hyperkalemia Indication Strategy Report 2026: MR, Trials and Deals
Latest Hotspot
8 min read
Hyperkalemia Indication Strategy Report 2026: MR, Trials and Deals
21 July 2026
Hyperkalemia indication strategy report covering epidemiology, MR biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Calciphylaxis Indication Strategy Report 2026: TNFRSF11B, Trials and Deals
Latest Hotspot
8 min read
Calciphylaxis Indication Strategy Report 2026: TNFRSF11B, Trials and Deals
21 July 2026
Calciphylaxis indication strategy report covering epidemiology, TNFRSF11B biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Anti-GBM disease Indication Strategy Report 2026: C5, Trials and Deals
Latest Hotspot
8 min read
Anti-GBM disease Indication Strategy Report 2026: C5, Trials and Deals
21 July 2026
Anti-GBM disease indication strategy report covering epidemiology, C5 biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Nephropathic cystinosis Indication Strategy Report 2026: CTNS, Trials and Deals
Latest Hotspot
8 min read
Nephropathic cystinosis Indication Strategy Report 2026: CTNS, Trials and Deals
21 July 2026
Nephropathic cystinosis indication strategy report covering epidemiology, CTNS biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Autosomal recessive polycystic kidney disease Indication Strategy Report 2026: PKHD1, Trials and Deals
Latest Hotspot
8 min read
Autosomal recessive polycystic kidney disease Indication Strategy Report 2026: PKHD1, Trials and Deals
21 July 2026
Autosomal recessive polycystic kidney disease indication strategy report covering epidemiology, PKHD1 biology, active trials, competition and deal signals using...
Read →
Hepatorenal syndrome Indication Strategy Report 2026: AVPR1A, Trials and Deals
Latest Hotspot
8 min read
Hepatorenal syndrome Indication Strategy Report 2026: AVPR1A, Trials and Deals
21 July 2026
Hepatorenal syndrome indication strategy report covering epidemiology, AVPR1A biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Acute kidney injury Indication Strategy Report 2026: TIM1, Trials and Deals
Latest Hotspot
8 min read
Acute kidney injury Indication Strategy Report 2026: TIM1, Trials and Deals
21 July 2026
Acute kidney injury indication strategy report covering epidemiology, TIM1 biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Nephrotic syndrome Indication Strategy Report 2026: CD80, Trials and Deals
Latest Hotspot
8 min read
Nephrotic syndrome Indication Strategy Report 2026: CD80, Trials and Deals
21 July 2026
Nephrotic syndrome indication strategy report covering epidemiology, CD80 biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
IgA vasculitis nephritis Indication Strategy Report 2026: BAFF, Trials and Deals
Latest Hotspot
8 min read
IgA vasculitis nephritis Indication Strategy Report 2026: BAFF, Trials and Deals
21 July 2026
IgA vasculitis nephritis indication strategy report covering epidemiology, BAFF biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →